These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38642081)

  • 41. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
    Zhang G; Schetter A; He P; Funamizu N; Gaedcke J; Ghadimi BM; Ried T; Hassan R; Yfantis HG; Lee DH; Lacy C; Maitra A; Hanna N; Alexander HR; Hussain SP
    PLoS One; 2012; 7(2):e31507. PubMed ID: 22363658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
    Donahue TR; Nguyen AH; Moughan J; Li L; Tatishchev S; Toste P; Farrell JJ
    J Surg Oncol; 2014 Dec; 110(8):952-9. PubMed ID: 25132574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
    Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A
    J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
    PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 49. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
    Matsubara J; Ono M; Honda K; Negishi A; Ueno H; Okusaka T; Furuse J; Furuta K; Sugiyama E; Saito Y; Kaniwa N; Sawada J; Shoji A; Sakuma T; Chiba T; Saijo N; Hirohashi S; Yamada T
    Mol Cell Proteomics; 2010 Apr; 9(4):695-704. PubMed ID: 20061307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
    Patzak MS; Kari V; Patil S; Hamdan FH; Goetze RG; Brunner M; Gaedcke J; Kitz J; Jodrell DI; Richards FM; Pilarsky C; Gruetzmann R; Rümmele P; Knösel T; Hessmann E; Ellenrieder V; Johnsen SA; Neesse A
    EBioMedicine; 2019 Feb; 40():394-405. PubMed ID: 30709769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
    Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
    J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
    Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
    Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
    Ohuchida K; Mizumoto K; Kayashima T; Fujita H; Moriyama T; Ohtsuka T; Ueda J; Nagai E; Hashizume M; Tanaka M
    Ann Surg Oncol; 2011 Aug; 18(8):2381-7. PubMed ID: 21347785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
    Schäfer C; Seeliger H; Bader DC; Assmann G; Buchner D; Guo Y; Ziesch A; Palagyi A; Ochs S; Laubender RP; Jung A; De Toni EN; Kirchner T; Göke B; Bruns C; Gallmeier E
    J Cell Mol Med; 2012 Aug; 16(8):1776-91. PubMed ID: 22004109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
    Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
    Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.